To observe the effect of vonoprazan quadruple 14-day therapy on Helicobacter pylori （Hp） infection.

A total of 120 Hp positive patients were included and divided into treatment group and control group, 60 cases in each group. The treatment group was given vonoprazan 20 mg + bismuth potassium citrate 220 mg + amoxicillin 1 000 mg+ furazoldone 100 mg, and the control group was given omeprazole 20 mg+ amoxicillin 1 000 mg+ bismuth potassium citrate 220 mg+ furazoldone 100 mg, twice a day for 14 days. The ¹⁴C-urea breath test was performed in all patients 4 to 6 weeks after the course of treatment, and the eradication rate of Hp and the occurrence of adverse reactions in the two groups were observed respectively.

Among the 120 patients included, there were 57 males and 63 females, aged from 20 to 69 years old, with an average age of （37.9±5.4） years. The Hp eradication rate in the treatment group was higher than that in the control group （97% vs. 80%, P < 0.05）. There was no significant difference in the incidence of adverse reactions between the two groups （P > 0.05）.

Quadruple 14-day therapy with vonoprazan is a safe and highly effective treatment for Hp eradication and can be used as a first- and second-line treatment.